The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple myeloma

Area of Science:

• Biochemistry
• Oncology
• Nephrology

Background:

• Multiple myeloma frequently causes skeletal complications.
• Accurate monitoring of bone disease in multiple myeloma is crucial for patient management.

Purpose of the Study:

• To evaluate the utility of simple postabsorptive urine hydroxyproline (Spot-HYPRO) and its fractions in diagnosing and monitoring bone disease in multiple myeloma patients.

Main Methods:

• Measurement of total Spot-HYPRO, dialyzable, and non-dialyzable (ND) fractions in 28 multiple myeloma patients and controls.
• Comparison of Spot-HYPRO levels between myeloma patients with and without bone disease, and those with and without renal disease.
• Correlation analysis of Spot-HYPRO and its fractions with the progression of bone disease in a subset of patients.

Main Results:

• Myeloma patients with bone disease exhibited significantly higher total Spot-HYPRO and dialyzable fractions compared to those without bone disease and controls (P < 0.001).
• The ND fraction of Spot-HYPRO was elevated in myeloma patients with renal disease compared to those without renal disease and controls (P < 0.01).
• Follow-up studies showed a strong correlation between Spot-HYPRO, its dialyzable fraction, and the evolution of bone disease.

Conclusions:

• Spot-HYPRO, particularly its dialyzable fraction, serves as a simple, cost-effective, and accurate biomarker for diagnosing and monitoring skeletal disease in multiple myeloma.
• This urine test can aid clinicians in the management of bone complications associated with multiple myeloma.